Literature DB >> 26165615

Postoperative complications are predictive of poor prognosis in hepatocellular carcinoma.

Norifumi Harimoto1, Ken Shirabe2, Toru Ikegami2, Tomoharu Yoshizumi2, Takashi Maeda3, Kiyoshi Kajiyama4, Takeharu Yamanaka5, Yoshihiko Maehara2.   

Abstract

BACKGROUND: A retrospective study was performed at some high-volume institutions to clarify the prognostic significance of postoperative complications in patients who had undergone hepatectomy for hepatocellular carcinoma (HCC). No published studies have investigated the relationship between postoperative complications of Clavien-Dindo grade III or more and prognosis in patients who have undergone hepatic resection.
METHODS: Patient data were retrospectively collected for 966 consecutive patients who had undergone hepatectomy for HCC with curative intent between January 2004 and December 2012. The patients were assigned to two groups according to the presence of postoperative complications. Clinicopathologic, surgical outcome, and long-term survival data were analyzed.
RESULTS: Hospital deaths occurred in nine patients (0.9%). Postoperative complications were identified in 165 patients (17.1%). Compared with patients without complications, patients with complications had significantly larger tumors, more advanced-stage tumors, more poorly differentiated tumors, more intrahepatic metastasis, longer operation time, greater blood loss, more blood transfusion, and more anatomic resection and combined resection. The overall 5-y survival rates were 48.6% in patients with postoperative complications and 73.2% in patients without them. The 5-y recurrence-free survival rates were 23.7% in patients with postoperative complications and 36.7% in patients without them. Multivariate analysis revealed that longer operation time and lower serum albumin level of albumin were independent predictive factors for occurrence of postoperative complications.
CONCLUSIONS: In patients with HCC, posthepatectomy complications are predictive of a worse overall survival, even when adjustments have been made for other known predictors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatectomy; Hepatocellular carcinoma; Postoperative complication; Prognosis

Mesh:

Year:  2015        PMID: 26165615     DOI: 10.1016/j.jss.2015.06.012

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  20 in total

1.  No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma: a propensity score matching analysis.

Authors:  T Peng; G Zhao; L Wang; J Wu; H Cui; Y Liang; R Zhou; Z Liu; Q Wang
Journal:  Clin Transl Oncol       Date:  2017-10-27       Impact factor: 3.405

2.  Impact of surgical complications on the risk of hepatocellular carcinoma recurrence after hepatic resection.

Authors:  Riccardo Pravisani; Umberto Baccarani; Miriam Isola; Gianluigi Adani; Dario Lorenzin; Giovanni Terrosu; Andrea Risaliti
Journal:  Updates Surg       Date:  2017-09-15

3.  Pleural Effusion After Hepatectomy for Hepatocellular Carcinoma: Risk Factor Analyses and Its Impact on Oncological Outcomes.

Authors:  Hideaki Uchiyama; Norifumi Harimoto; Shinji Itoh; Tomoharu Yoshizumi; Toru Ikegami; Yoshihiko Maehara
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

4.  Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years.

Authors:  Yo-Ichi Yamashita; Katsunori Imai; Takayoshi Kaida; Takanobu Yamao; Masayo Tsukamoto; Shigeki Nakagawa; Hirohisa Okabe; Akira Chikamoto; Takatoshi Ishiko; Tomoharu Yoshizumi; Tetsuo Ikeda; Yoshihiko Maehara; Hideo Baba
Journal:  Surg Endosc       Date:  2018-06-05       Impact factor: 4.584

5.  Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.

Authors:  Norifumi Harimoto; Tomoharu Yoshizumi; Kazuhito Sakata; Akihisa Nagatsu; Takashi Motomura; Shinji Itoh; Noboru Harada; Toru Ikegami; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

6.  Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Junjie Kong; Guangbing Li; Jiawei Chai; Guangsheng Yu; Yong Liu; Jun Liu
Journal:  Ann Surg Oncol       Date:  2021-06-23       Impact factor: 5.344

7.  Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.

Authors:  Cheng-Jun Sui; Yan-Ming Zhou; Wei-Feng Shen; Bing-Hua Dai; Jiong-Jiong Lu; Min-Feng Zhang; Jia-Mei Yang
Journal:  J Mol Med (Berl)       Date:  2016-07-05       Impact factor: 4.599

8.  Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results.

Authors:  Gisele N'Kontchou; Jean-Charles Nault; Olivier Sutter; Valerie Bourcier; Emmanuelle Coderc; Veronique Grando; Pierre Nahon; Nathalie Ganne-Carrié; Abou Diallo; Nicolas Sellier; Olivier Seror
Journal:  Liver Cancer       Date:  2018-06-28       Impact factor: 11.740

9.  Frailty Predicts Severe Postoperative Complication after Elective Hepatic Resection.

Authors:  Hirohisa Okabe; Hiromitsu Hayashi; Takaaki Higashi; Hidetoshi Nitta; Yoshiaki Ikuta; Toshihiko Yusa; Hideaki Takeyama; Katsuhiro Ogawa; Nobuyuki Ozaki; Shinichi Akahoshi; Kenichi Ogata; Takayuki Osaki; Hideo Baba; Hiroshi Takamori
Journal:  Gastrointest Tumors       Date:  2019-05-22

10.  The evolution of surgical treatment for gastrointestinal cancers.

Authors:  Yoshihiko Maehara; Yuji Soejima; Tomoharu Yoshizumi; Naoyuki Kawahara; Eiji Oki; Hiroshi Saeki; Tomohiko Akahoshi; Toru Ikegami; Yo-Ichi Yamashita; Tadashi Furuyama; Keishi Sugimachi; Noboru Harada; Tetsuzo Tagawa; Norifumi Harimoto; Shinji Itoh; Hideto Sonoda; Koji Ando; Yuichiro Nakashima; Yoshihiro Nagao; Nami Yamashita; Yuta Kasagi; Takafumi Yukaya; Takeshi Kurihara; Ryosuke Tsutsumi; Shinkichi Takamori; Shun Sasaki; Tetsuo Ikeda; Yoshikazu Yonemitsu; Takasuke Fukuhara; Hiroyuki Kitao; Makoto Iimori; Yuki Kataoka; Takeshi Wakasa; Masami Suzuki; Koji Teraishi; Yasuto Yoshida; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2019-09-14       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.